On the afternoon of May 29, Yang Zhouhong, Vice County Mayor of Ninghai County, led a delegation including heads of the County Market Supervision Administration and relevant functional departments to Zhejiang Tianyuan Biotechnology Co., Ltd. for on-site research and inspection. Jiao Mingming, General Manager of Tianyuan Biotechnology, together with the company's management team, warmly received the delegation and accompanied them throughout the visit and exchange.

      During the visit, Vice County Mayor Yang Zhouhong and the delegation conducted an in-depth tour of the enterprise exhibition hall and core laboratories of Tianyuan Biotechnology's Ninghai Branch. Through on-site visits and briefings, the delegation gained a detailed understanding of Tianyuan Biotechnology's strategic layout in the biopharmaceutical field, its technology platform development, and its achievements in recent years.

      During the tour, the delegation focused particular attention on Tianyuan Biotechnology's scientific research and innovation progress in the field of induced pluripotent stem cells (iPS cells). Vice County Mayor Yang Zhouhong noted that the biopharmaceutical industry is a strategic emerging industry with enormous development potential, and that Tianyuan Biotechnology, as a national high-tech enterprise rooted in Ninghai, has demonstrated strong strength and vitality in scientific research, innovation, and technological breakthroughs. He emphasized that relevant functional departments should further strengthen their service awareness, take proactive steps and provide targeted support, and enhance cross-departmental coordination to address the practical difficulties encountered by enterprises in their development—effectively resolving problems for enterprises, striving to create a better business environment, and providing solid policy and service guarantees for enterprises' sustained innovation and development.

      Jiao Mingming, General Manager of Tianyuan Biotechnology, expressed sincere gratitude to the County Party Committee, the County Government, various functional departments, and the Biopharmaceutical Industrial Park for their long-standing care and support. He stated that Tianyuan Biotechnology will continue to uphold its corporate mission of "Gathering the Essence of Science, Safeguarding Human Health," continue to increase R&D investment in cutting-edge fields such as iPS cells, continuously enhance its independent innovation capabilities, and contribute to the high-quality development of the local biopharmaceutical industry.

      This research visit and guidance not only reflected the high importance that the Ninghai County Party Committee and County Government attach to Tianyuan Biotechnology's development, but also pointed out the direction for the company's future strategic planning and industrial upgrading. Tianyuan Biotechnology will take this opportunity to continue deepening industry-academia-research cooperation, accelerate the translation of scientific research achievements, and drive the company to new heights with higher standards and stricter requirements.

      Participants in the research visit included Wang Donghai, Jiang Huiqin, and Liu Xiangcun from the Ninghai County Market Supervision Administration, and Zhang Qiong and Cao Ningbo from the County Biopharmaceutical Industrial Park Management Center.

      Founded in 2017, Zhejiang Tianyuan Biotechnology Co., Ltd. is a platform-based biopharmaceutical enterprise driven by AI + iPSC technology and dedicated to developing drugs for heart failure treatment. With its iPS seed cell bank, tumor cell bank, and HLA compatibility matching system as cornerstones, the company has built a full-chain R&D platform covering cell reprogramming, disease model construction, and candidate drug validation. Leveraging the policy advantages of Hainan's "Medical Special Zone," the company has opened up the "last mile" of clinical translation; through its regional network of facilities, it has achieved integrated operations spanning collection, preparation, R&D, and application; and with a closed-loop marketing ecosystem, it connects medical institutions, research platforms, and end users.